OBJECTIVE -The International Diabetes Federation (IDF) has recently established a worldwide consensus definition of the metabolic syndrome. No prospective data are available on the cardiovascular risk associated with this new metabolic syndrome definition.
T he term metabolic syndrome refers to a cluster of cardiovascular risk factors associated with insulin resistance (1, 2) . During the past decade, there have been various attempts to standardize the definition of the metabolic syndrome as a diagnostic category, with several institutions proposing various criteria (3) (4) (5) (6) (7) .
The definition of the metabolic syndrome that has most often been used in the literature was proposed by the National Cholesterol Education Program's Adult Treatment Panel III (ATPIII) 4 years ago (4) . According to this definition, the metabolic syndrome is diagnosed in the presence of any three of five markers: central obesity, high triglycerides, low HDL cholesterol, high fasting glucose, and high blood pressure.
Recently, the concept of the metabolic syndrome as an entity with clinical implications over and above its single constituents has been challenged (8, 9) . However, efforts continue to integrate the individual metabolic syndrome traits into an overall diagnosis, and the International Diabetes Federation (IDF) has now established a worldwide consensus definition of the metabolic syndrome (10, 11) .
This new definition basically agrees with the component features of the ATPIII definition but introduces some important changes: the cutoff for a waist circumference defining central obesity has been considerably lowered for both men (from 102 to 94 cm) and women (from 88 to 80 cm), and the presence of central obesity is mandatory in this new definition. Also, the cutoff for elevated fasting glucose has been lowered in accordance with the American Diabetes Association's recommendation (12) , and, importantly, patients receiving treatment for metabolic syndrome components are considered to meet the respective criteria, whereas therapy was not explicitly considered in the ATPIII definition.
The metabolic syndrome as defined by ATPIII criteria confers a strongly increased risk of vascular events (13) (14) (15) (16) (17) (18) (19) . However, no prospective data are available on the cardiovascular risk associated with the new IDF definition. We therefore aimed at investigating the power of the ATPIII and IDF definitions of the metabolic syndrome as predictors of future vascular events in a high-risk cohort of coronary patients. Further, we intended to investigate whether the integral diagnosis of the metabolic syndrome is a better predictor of vascular events than
the individual metabolic syndrome components.
RESEARCH DESIGN AND METHODS -The design of this prospective cohort study has been described in detail earlier (19, 20) . In brief, we enrolled 756 consecutive Caucasian patients referred to coronary angiography for routine evaluation of established or suspected coronary artery disease (CAD). Six patients with type 1 diabetes (Cpeptide negative) were excluded from the analyses. The ethics committee of the University of Innsbruck approved the present study, and all participants gave written informed consent.
At baseline, coronary angiography was performed with the Judkins technique. Stenoses Ն50% were considered significant, and coronary arteries were defined as angiographically normal in the absence of any visible lumen narrowing at angiography, as described previously (21, 22) .
From the 750 patients included in the analyses, 164 had diabetes according to World Health Organization criteria (23) and 586 did not have diabetes. Among patients with diabetes, 42.7% were not receiving any antidiabetic medication and 34.8, 32.3, 24.4, and 1.2% were receiving-alone or in combinationsulfonylurea, biguanides, insulin, and ␣-glucosidase inhibitors, respectively. Overall, 64.7% of our patients were on aspirin, 31.3% on statins, 2.9% on fibrates, 12.1% on calcium antagonists, 47.1% on ␤-blocking agents, 36.0% on ACE inhibitors, and 3.9% on angiotensin II blocking agents.
According to ATPIII criteria (4), the metabolic syndrome was diagnosed in the presence of any three of the following: waist circumference Ͼ102 cm in men and Ͼ88 cm in women, triglycerides Ն150 mg/dl (1.7 mmol/l), HDL cholesterol Ͻ40 mg/dl (1.0 mmol/l) in men and Ͻ50 mg/dl (1.3 mmol/l) in women, blood pressure Ն130/Ն85 mmHg, or fasting glucose Ն110 mg/dl (6.1 mmol/l). Using IDF criteria (10), the metabolic syndrome was diagnosed in patients who had a high waist circumference (Ն94 cm in men and Ն80 cm in women) plus any two of the following: triglycerides Ն150 mg/dl (1.7 mmol/l) or specific treatment for this lipid abnormality, HDL cholesterol Ͻ40 mg/ day (1.0 mmol/l) in men and Ͻ50 mg/dl (1.3 mmol/l) in women or specific treatment for this lipid abnormality, systolic blood pressure Ն130 or diastolic blood pressure Ն85 mg/dl or treatment of previously diagnosed hypertension, and fasting plasma glucose Ն100 mg/dl (5.6 mmol/l) or previously diagnosed type 2 diabetes.
Prospective study During a follow-up period of 3.9 Ϯ 0.8 years, we recorded fatal and nonfatal cardiovascular events, including coronary death (fatal myocardial infarction, sudden cardiac death, and mortality from congestive heart failure due to CAD), fatal ischemic stroke, nonfatal myocardial infarction, nonfatal ischemic stroke, and need for coronary artery bypass grafting, percutaneous coronary intervention, or noncoronary revascularization. Angina pectoris per se was not included among the end points.
Statistical analysis
Differences in baseline characteristics were tested for statistical significance with the 2 test and the Mann-Whitney U test for categorical and continuous variables, respectively. The Wilcoxon-Gehan statistic was used to compare differences in the cumulative incidence rates of vascular events. Adjusted hazard ratios (HRs) for the incidence of vascular events were derived from Cox proportional hazards models; for these calculations, continuous variables were z transformed. Results are given as means Ϯ SD if not denoted otherwise. All statistical analyses were performed with the software package SPSS 11.0 for Windows.
RESULTS
Baseline characteristics with respect to metabolic syndrome status From the total study population, 280 patients (37.3%) met the ATPIII criteria and 341 patients (45.5%) the IDF criteria for the metabolic syndrome. Baseline characteristics of patients with respect to the metabolic syndrome status according to the ATPIII and IDF definitions are summarized in Table 1 .
Prevalence of the individual metabolic syndrome criteria From the individual ATPIII metabolic syndrome criteria, the blood pressure criterion was most frequently (in 85.4%) met in patients with the metabolic syndrome according to the ATPIII definition, followed by the criteria for triglycerides (75.0%), fasting plasma glucose (70.4%), HDL cholesterol (68.9%), and waist circumference (59.3%). From the patients with the metabolic syndrome according to the IDF definition, 100, 89.4, 83.9, 59.2, and 52.2% fulfilled the IDF criteria for waist circumference, blood pressure, fasting plasma glucose, triglycerides, and HDL cholesterol, respectively.
Concordance of the two definitions
Concordance between the ATPIII and IDF definitions was moderate (Cohencoefficient ϭ 0.522; P Ͻ 0.001). From our 280 patients (37.3% of the total study population) with the metabolic syndrome according to the ATPIII definition, 223 (79.6%) also had the metabolic syndrome according to the IDF definition; from the 470 patients who did not have the ATPIII metabolic syndrome (62.7% of the total study population), 352 (74.9%) also did not fulfil the criteria of the IDF definition (online appendix [available from http:// care.diabetesjournals.org]). Thus, 57 patients (7.6% of the total study cohort) fulfilled the ATPIII criteria but not the IDF criteria (ATPIIIϩ/IDFϪ group), and 118 patients (15.7% of the total study cohort) fulfilled the IDF criteria but not the ATPIII criteria (ATPIIIϪ/IDFϩ group).
Differences between the discordant groups By definition, all ATPIIIϪ/IDFϩ patients met the IDF waist criterion. No ATPIIIϩ/ IDFϪ patient fulfilled the ATPIII waist criterion. ATPIIIϪ/IDFϩ patients less frequently than ATPIIIϩ/IDFϪ patients met the respective triglycerides (30.5 vs. 86.0%; P Ͻ 0.001) and HDL (24.6 vs. 77.2%; P Ͻ 0.001) criteria. There were no significant differences in the prevalence of the respective blood pressure (83.9 vs. 84.2%; P ϭ 0.958) and glucose (78.0 vs. 68.4%; P ϭ 0.173) criteria between these subgroups.
Incidence of vascular events
During a mean (ϮSD) follow-up time of 3.9 Ϯ 0.8 years, we recorded 160 vascular end points, encompassing 42 coronary deaths, 12 fatal ischemic strokes, 13 nonfatal myocardial infarctions, 14 nonfatal ischemic strokes, 23 coronary artery bypass graftings, 33 percutaneous coronary interventions, and 23 revascularizations at the carotid (n ϭ 6) or peripheral (n ϭ 17) arteries. Thus, the overall incidence rate was 21.3%. Impact of new and old criteria of the metabolic syndrome on the incidence of vascular events Event-free survival was significantly lower (P Ͻ 0.001) in patients with the metabolic syndrome according to the ATPIII definition than in patients who did not meet the ATPIII criteria for the diagnosis of the metabolic syndrome (Fig.  1A) . In Cox regression analyses adjusting for age, sex, smoking, LDL cholesterol, and baseline CAD, the ATPIII metabolic syndrome proved strongly and independently predictive of vascular events, with an adjusted HR of 1. (Table 2) . When patients receiving treatment for individual metabolic syndrome traits were considered to meet the respective criteria for these traits, the thus-modified ATPIII definition of the metabolic syndrome significantly predicted vascular events after adjustment for age, sex, smoking, LDL cholesterol, and baseline CAD (adjusted HR 1.810 [95% CI 1.299 -2.520]; P Ͻ 0.001). Also, a modified ATPIII definition that was recently proposed by the American Heart Association and the National Heart, Lung, and Blood Institute (7), which considers treatment and uses a fasting glucose of 100 mg/dl as a cutoff for the high-glucose criterion, significantly predicted vascular events in our patient cohort (1.634 [1.173-2.276]; P ϭ 0.004). Further, the metabolic syndrome as defined by World Health Organization criteria (3) proved significantly predictive of vascular events (1.405 [1.011-1.953]; P ϭ 0.043).
In patients with the metabolic syndrome according to the IDF definition, event-free survival was not significantly different (P ϭ 0.283) from patients who did not fulfil the IDF criteria for the diagnosis of the metabolic syndrome (Fig.   1B) . Also, in Cox regression analysis adjusting for age, sex, smoking, LDL cholesterol, and baseline CAD, the IDF metabolic syndrome was not significantly associated with vascular events, with an adjusted HR of 1.189 (95% CI 0.859 -1.646; P ϭ 0.297).
The incidence of vascular events was significantly lower (P ϭ 0.012) among ATPIIIϪ/IDFϩ patients than among AT-PIIIϩ/IDFϪ patients (Fig. 1C) . Cox regression analysis adjusting for age, sex, smoking, LDL cholesterol, diabetes status, and baseline CAD confirmed that AT-PIIIϩ/IDFϪ patients had a significantly worse prognosis than ATPIIIϪ/IDFϩ patients, with an adjusted HR of 2.073 (95% CI 1.012-4.246; P ϭ 0.046).
The metabolic syndrome, its individual components, and vascular risk Table 2 summarizes the cardiovascular risks related to the dichotomous diagnosis of the metabolic syndrome and to its single components. In Cox regression analyses adjusting for age, sex, smoking, 
Specific study end points
In analyses focusing on specific secondary study end points, the ATPIII metabolic syndrome after adjustment for age, sex, smoking, LDL cholesterol, and baseline CAD proved significantly predictive of end points related to CAD (n ϭ 111), with an adjusted HR of 1.708 (1.158 -2.519; P ϭ 0.007). The IDF metabolic syndrome in contrast was not associated with CADrelated end points (0.945 [0.642-1.389]; P ϭ 0.772). We did not observe significant associations between either metabolic syndrome category and the smaller number (n ϭ 32) of end points related to cerebrovascular disease ( . There was no significant difference in the impact of the metabolic syndrome on vascular events between men and women, irrespective of whether the ATPIII criteria or the IDF criteria were applied (P interaction ϭ 0.313 and 0.903, respectively). When patients with diabetes (n ϭ 164) were excluded from the analyses, of the remaining 586 nondiabetic patients, 168 (28.7%) had the metabolic syndrome according to ATPIII criteria and 229 (39.1%) met the IDF criteria for the diagnosis of the metabolic syndrome. Consistent with the total study cohort, the metabolic syndrome as defined by ATPIII criteria significantly predicted vascular events in nondiabetic patients (HR 1.531 [95% CI 1.007-2.328]; P ϭ 0.046), whereas the metabolic syndrome as defined by IDF criteria did not significantly predict vascular events in these patients (1.139 [0.765-1.695]; P ϭ 0.522).
CONCLUSIONS -From our results, we conclude that among angiographied coronary patients the ATPIII definition and the IDF definition of the metabolic syndrome do not identify the same patients. The metabolic syndrome as defined by ATPIII criteria confers a higher risk of vascular events than the metabolic syndrome as defined by IDF criteria.
The prevalence of the metabolic syndrome defined according to the IDF definition in our investigation was higher than the metabolic syndrome defined according to the ATPIII definition. Concordantly, Athyros et al. (24) have found a higher prevalence of the metabolic syndrome diagnosed according to IDF criteria in a Greek population-based study, and Ford (25) described a higher prevalence of the IDF metabolic syndrome among adults in the U.S. A recent investigation from northern Mexico reported a high concordance between the ATPIII and IDF definitions of the metabolic syndrome (26) . However, in 23.3% of our Caucasian patients the two metabolic syndrome definitions led to discordant diagnoses; thus, concordance was moderate.
The IDF wanted its new definition to encourage the identification of patients at increased risk of cardiovascular events (10). However, in our study population, we did not find a significant association between vascular events and the IDF metabolic syndrome, whereas the metabolic syndrome as defined according to ATPIII criteria was strongly predictive of future vascular events. The incidence of vascular events was significantly higher in patients who met the ATPIII criteria but not the IDF criteria for the diagnosis of the metabolic syndrome than in patients who met the IDF criteria but not the ATPIII criteria.
There are important differences between the ATPIII and IDF definitions of the metabolic syndrome that may explain the weaker association of the IDF metabolic syndrome with vascular events. First, the lowering of the cutoff value for waist circumference leads to the inclusion of patients with a relatively lower level of this risk factor in the IDF category of the metabolic syndrome. Second, the mandatory status of the waist criterion in the new definition results in a relatively lower prevalence of other (potentially stronger) metabolic syndrome risk factors in patients with the metabolic syndrome. In particular, the high triglycerides and low HDL cholesterol metabolic syndrome components are relatively underrepresented in patients with the IDF metabolic syndrome. However, the greatest vascular risk in our investigation was conferred by these lipid traits. Concordant with this finding, high triglycerides and low HDL cholesterol were the only metabolic syndrome components that were independently associated with myocardial infarction and stroke in an evaluation of data from the third National Health and Nutrition Examination Survey (27) . Consistent with their less pronounced dyslipidemia, patients with the metabolic syndrome according to the IDF definition had a lower degree of homeostasis model assessment of insulin resistance (Table 1) , which is a strong cardiovascular risk factor among coronary patients (19) . Third, in the IDF definition, patients receiving treatment for metabolic syndrome components are considered to meet the respective criteria, whereas therapy was not explicitly considered in the ATPIII definition. Treatment of risk factors possibly could dilute their effects on prognosis and thus weaken their prognostic power. However, in our investigation, a modification of the ATPIII category in which treatment was considered still proved strongly predictive for vascular events. Thus, the consideration of treatment in the IDF definition of the metabolic syndrome does not appear to account for its weak association with vascular events.
A recent report from a population with a high proportion of Mexican Americans suggested that the increased vascular risk of patients with the metabolic syndrome is entirely due to the high prevalence of patients with diabetes among subjects with the metabolic syndrome (28) . However, in our population of Caucasian coronary patients, the metabolic syndrome defined according to ATPIII criteria conferred an increased vascular risk independent from the diabetic state.
Importantly, the cardiovascular risk associated with the ATPIII metabolic syndrome in our patients resided basically in its lipid components. Moreover, our data suggest that these lipid traits are better predictors of vascular events than the clinical category of the metabolic syndrome itself and thus lend support to recent criticism of the use of the metabolic syndrome as a clinical category in cardiovascular risk stratification (8, 9) . Of note, the decisive role of the dyslipidemic metabolic syndrome features in cardiovascular risk prediction is well in line with our recent report on the paramount impact of the low HDL/high triglyceride pattern on the short-term incidence of vascular events in patients with type 2 diabetes (20) .
In conclusion, patients with the metabolic syndrome according to the ATPIII definition are at a significantly higher risk of vascular events than patients with the metabolic syndrome diagnosed according to IDF criteria. However, as even the AT-PIII definition of the metabolic syndrome did not provide prognostic information beyond its dyslipidemic features, physicians in the care of coronary patients should pay more attention to the high triglyceride/low HDL pattern of dyslipidemia. Evaluations of new and old criteria for the metabolic syndrome in other populations as well as interventional data on the potential of cardiovascular risk reduction residing in an improvement of the high triglycerides and low HDL traits in patients with the metabolic syndrome are urgently needed.
